Sign in

Dave Turkaly

Managing Director and Senior Equity Research Analyst at Citizens

Dave Turkaly is a Managing Director and Senior Equity Research Analyst at Citizens JMP, specializing in healthcare with a focus on the medical device and orthopedics sector. He covers companies such as Orthopediatrics (KIDS), Steris (STE), and Haemonetics (HAE), and has issued notable ratings including a +416.9% return on STIM and consistent recommendations driving sector insights. With a career spanning over a decade, Turkaly transitioned to Citizens JMP after previous experience at JMP Securities, contributing deep analytical expertise and market perspective. He is a FINRA-registered analyst holding relevant securities licenses, and is recognized for his rigorous company coverage and impactful stock rating performance, maintaining a 41% success rate and clear public visibility.

Dave Turkaly's questions to Apyx Medical (APYX) leadership

Question · Q3 2025

Dave Turkaly asked for clarification on the reported decrease in generator sales, specifically how it relates to the Aon system launch and its impact on gross margins.

Answer

CEO Charlie Goodwin explained that the reclassification of sales due to the Aon system launch impacts generator sales reporting, as Aon sales now encompass Apex One generators. He also stated that the company is not providing specific revenue or gross margin guidance for Aon but reiterated that the surgical aesthetics business, particularly in the U.S., historically yields the highest gross margins.

Ask follow-up questions

Fintool

Fintool can predict Apyx Medical logo APYX's earnings beat/miss a week before the call

Question · Q3 2025

Dave Turkaly asked for clarification on the decline in generator sales, specifically how AYON sales classification impacts these figures, and inquired about the anticipated gross margin impact and potential uptick from AYON's rollout.

Answer

CEO Charlie Goodwin explained that generator sales are now classified under AYON sales, as AYON systems either integrate existing Apyx One generators, require an upgrade from RS3, or include a new Apyx One. He declined to provide specific gross margin guidance but noted that the Surgical Aesthetics business, particularly in the U.S., has the highest gross margins, benefiting the company overall.

Ask follow-up questions

Fintool

Fintool can write a report on Apyx Medical logo APYX's next earnings in your company's style and formatting

Let Fintool AI Agent track Dave Turkaly for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free